Dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for prurigo nodularis

Approval based on direct-to-phase 3 program showing more than three times as many dupixent patients (60% and 58%) experienced clinically meaningful itch reduction at 24 weeks compared to placebo (18% and 20%) dupixent also significantly reduced skin lesions and improved health-related quality of life compared to placebo in europe, about 70,000 adults living with prurigo nodularis are most in need of new treatment options dupixent now approved to treat four chronic inflammatory diseases in the eu tarrytown, n.y. and paris , dec. 15, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european commission (ec) has expanded the marketing authorization for dupixent® (dupilumab) in the european union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
REGN Ratings Summary
REGN Quant Ranking